• June 10, 2022

This article discusses CFD simulations of nasal spray transport and use of CFD modeling to design nasal spray devices and analyze spray delivery performance. In silico testing using CFD, guided with in vitro measurements, is a potentially valuable approach that can reduce time and costs of evaluating nasal spray delivery performance under variable usage conditions […]

Dry powder inhalation (DPI) products basically consist of a powder formulation and a device. The formulation, which contains active pharmaceutical ingredient(s) (APIs) micronized to inhalable particle size and a few excipients may, at first glance, appear simple. However, a large number of factors are critical to the performance of dry powder formulations for inhalation. Furthermore, […]

  • February 11, 2022

This article describes legislative and commercial drivers for propellant change and potential propellants, as well as the Respitab® technology platform, which provides a novel approach to formulation and manufacturing of lower global warning potential (GWP) pMDIs. Studies are presented and manufacturing and considerations for its use are discussed. There is a clear need for alternatives […]

  • December 7, 2021

The need for accurate thermophysical property prediction for diverse formulation mixtures is expected to grow, as next-generation formulations with low global warming potential (GWP) are introduced and as usage of predictive simulation increases during pMDI development. This need can be supported by appropriate experimental measurement campaigns for formulation mixtures, spanning the full range of temperature, […]

For many years, the nasal route of administration has been used very successfully for the non-invasive delivery of small molecule drugs. The anatomy and physiology of the nasal cavity have been exploited to deliver 1) locally acting medications, to combat ailments such as seasonal and year-round allergies, 2) systemically delivered drugs, via the highly vascularized […]

  • June 9, 2021

There is a need to adopt more environmentally friendly pMDI propellants, not only to reduce carbon footprint, but also to mitigate supply issues that may result from the decline in the use of existing propellants. HFA-152a and HFO-1234ze(E) are two potential candidates. It is critical that drug developers and manufacturers prepare their facilities for the […]

As the inhalation community explores propellants with lower global warming potential that could be used in pressurized metered dose inhalers (pMDIs), we hear the term “Kigali Amendment to the Montreal Protocol.” But how does that differ from the Paris Agreement? A useful explanation is shown in this table, reprinted with kind permission of the Montreal […]

  • February 10, 2021

“Excessive SABA use is only one indicator for poor asthma control but the risks are not well understood by patients and are often overlooked by healthcare professionals,” said the lead investigator. According to the ERS article, “the study’s findings are now being used to support and inform a three-year program that provides general practices with […]

When repurposing oral or parenteral therapies for inhaled administration, there are a number of important factors to evaluate early in the drug development process. Considering these factors may increase chances that a repurposed product could be positioned for successful clinical studies and commercial adoption by patients. A key question is, “Why are we repurposing the […]

Current therapies for pulmonary arterial hypertension do not provide a cure and their use can be limited due to systemic side effects. Consequently, there is a critical need to discover and develop new drugs that target vascular remodeling and provide long-term disease reversal benefits. Drug repurposing can bypass common challenges of drug discovery and offer […]